Lisinopril/hydrochlorothiazide
Combination of | |
---|---|
Lisinopril | ACE inhibitor |
Hydrochlorothiazide | Thiazide diuretic |
Names | |
Trade names | Zestoretic, Prinzide, others |
Clinical data | |
Pregnancy category | |
Routes of use | By mouth |
Defined daily dose | not established[1] |
External links | |
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a601070 |
Legal | |
Legal status |
|
(verify) |
Lisinopril/hydrochlorothiazide, sold under the trade name Zestoretic among others, is a combination of the medications lisinopril, an ACE inhibitor, and hydrochlorothiazide, a diuretic.[2] It is used to treat high blood pressure.[2] Typically, it becomes an option once a person is doing well on the individual components.[3] It is taken by mouth.[2]
Common side effects include dizziness, headache, cough, and feeling tired.[4] Severe side effects may include angioedema and low blood pressure.[4] Use during pregnancy may harm the baby.[4]
The combination was approved for medical use in the United States in 1989.[2] It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[3] In the United States the wholesale cost per dose is less than US$0.05 as of 2018[update].[6] In the United Kingdom it costs the NHS about GB£0.40 per dose as of 2017[update].[3] In 2017, it was the 44th most commonly prescribed medication in the United States, with more than 16 million prescriptions.[7][8]
Dosage
The defined daily dose is not established.[1]
References
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020.
- ↑ 2.0 2.1 2.2 2.3 "Hydrochlorothiazide and lisinopril Uses, Side Effects & Warnings". Drugs.com. Cerner Multum. Retrieved 26 December 2018.
- ↑ 3.0 3.1 3.2 British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. p. 166. ISBN 978-0857112989.
- ↑ 4.0 4.1 4.2 "Lisinopril and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Solco Healthcare LLC.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services. Retrieved 22 December 2018.
- ↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ↑ "Hydrochlorothiazide; Lisinopril - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
External links
Identifiers: |
---|
- "Hydrochlorothiazide mixture with Lisinopril". Drug Information Portal. U.S. National Library of Medicine.
![]() | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs that are a combination of chemicals
- Articles containing potentially dated statements from 2018
- All articles containing potentially dated statements
- Articles containing potentially dated statements from 2017
- Antihypertensive agents
- Combination drugs
- AstraZeneca brands
- World Health Organization essential medicines
- All stub articles
- Antihypertensive agent stubs